AstraZeneca plc (AZN) Stock Rating Reaffirmed by JPMorgan Chase & Co.
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a research report issued to clients and investors on Monday.
Other analysts have also recently issued reports about the company. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, June 23rd. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,600 ($69.31) target price on shares of AstraZeneca plc in a research report on Tuesday, June 14th. Societe Generale restated a “buy” rating and issued a GBX 6,900 ($85.40) target price on shares of AstraZeneca plc in a research report on Friday, June 24th. Berenberg Bank raised their target price on AstraZeneca plc from GBX 4,950 ($61.26) to GBX 5,400 ($66.83) and gave the company a “buy” rating in a research report on Tuesday, July 12th. Finally, Bryan, Garnier & Co restated a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, July 28th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 4,937.91 ($61.11).
AstraZeneca plc (LON:AZN) opened at 5051.00 on Monday. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The company has a 50-day moving average price of GBX 5,004.92 and a 200 day moving average price of GBX 4,463.08. The firm’s market capitalization is GBX 63.90 billion.
The business also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.85) per share. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.